Heilongjiang, China

Jiaji Liu

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Harbin Pharmaceutical Group Co., Ltd. General Pharmaceutical Factory. Active years: 2018.


% Patents Active = 100.0


Average Co-Inventor Count = 10.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jiaji Liu: Innovator in Diaza-Benzofluoranthrene Compounds

Introduction

Jiaji Liu is a notable inventor based in Heilongjiang, China. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on diaza-benzofluoranthrene compounds. His research and inventions have the potential to impact various therapeutic applications.

Latest Patents

Jiaji Liu holds 1 patent for his work on diaza-benzofluoranthrene compounds. This patent discloses a series of compounds that are represented by a specific formula, including pharmaceutically acceptable salts or tautomers thereof. His invention is aimed at enhancing the efficacy of pharmaceutical formulations.

Career Highlights

Jiaji Liu is associated with Harbin Pharmaceutical Group Co., Ltd., specifically the General Pharmaceutical Factory. His role in this esteemed organization has allowed him to focus on research and development in the pharmaceutical sector, contributing to advancements in drug formulation and delivery.

Collaborations

Jiaji Liu has collaborated with several talented individuals in his field, including Shujie Yuan and Xinchun Yang. These collaborations have fostered a productive environment for innovation and have led to the development of new pharmaceutical compounds.

Conclusion

Jiaji Liu's work in the field of diaza-benzofluoranthrene compounds exemplifies the spirit of innovation in pharmaceuticals. His contributions are paving the way for future advancements in drug development and therapeutic applications.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…